I85PREP
⌘ K
FPGEE study materials
FPGEE study resources

Vancomycin AUC Assessment in a Patient with a Rising Creatinine

FPGEE · Put your knowledge to work in context.

All case studies

Vancomycin AUC Assessment in a Patient with a Rising Creatinine

A 68-year-old man (95 kg, SCr 1.6 mg/dL, estimated CrCl 38 mL/min) is receiving vancomycin 1250 mg IV every 12 hours, each dose infused over 1.5 hours, for MRSA bacteremia. The isolate's vancomycin MIC is 1 mg/L by broth microdilution. He also receives piperacillin-tazobactam 4.5 g IV every 6 hours for a polymicrobial abdominal source and furosemide 40 mg daily. His SCr has drifted from 1.2 to 1.6 mg/dL over five days. Steady-state concentrations were drawn with the sixth dose: 31 mg/L drawn 2 hours after the end of the infusion, and 19 mg/L drawn immediately before the next dose. The team asks whether the regimen is adequate and whether the combination therapy is contributing to the renal trajectory.

1. Using the two concentrations, estimate the elimination rate constant, half-life, and steady-state AUC24. Is this regimen within the AUC/MIC target for MRSA?

Read the worked answer

Key assumptions: one-compartment, first-order elimination, true steady state, no change in clearance across the interval, and that the level drawn 2 hours post-infusion reflects the post-distribution phase (defensible, but sampling earlier would overestimate).

Timing: infusion starts at t = 0, ends at t = 1.5 h; the 'peak' is at t = 3.5 h; the trough is at t = 12 h. Interval = 8.5 h.

Elimination:

  • kₑ = ln(31/19) / 8.5 = 0.490 / 8.5 ≈ 0.058 h⁻¹
  • t½ = 0.693 / 0.058 ≈ 12 h (consistent with a CrCl in the 30s, though a bit long - supports a real decline in clearance)

AUC by back-extrapolation:

  • Concentration at end of infusion = 31 × e^(0.058×2) = 31 × 1.12 ≈ 34.8 mg/L
  • AUC during the 1.5-h infusion (trapezoid) = (19 + 34.8)/2 × 1.5 ≈ 40 mg·h/L
  • AUC of the elimination phase = (34.8 − 19)/0.058 ≈ 273 mg·h/L
  • AUC₁₂ ≈ 40 + 273 = 313 mg·h/L → AUC₂₄ ≈ 625 mg·h/L

Interpretation: AUC/MIC ≈ 625/1 = 625. The consensus target for MRSA is AUC₂₄/MIC 400–600, so this sits at or just above the ceiling - not grossly toxic, but with a creatinine that has risen 33% and a half-life of 12 hours, continued dosing at this exposure invites accumulation and vancomycin-associated AKI. AUC-based monitoring is preferred over trough-only monitoring; a trough of 19 mg/L is a crude surrogate and here overstates or understates poorly. Reassess after any dose change.

2. Recommend a specific regimen change and a monitoring plan. How do you handle the piperacillin-tazobactam question?

Read the worked answer

Regimen: Reduce exposure roughly 20–25% - vancomycin 1000 mg IV q12h is a reasonable starting point (or 750 mg q8h if the team prefers tighter peaks). Do not simply extend the interval to q24h in a bacteremic patient; the goal is AUC 400–600, not a low trough. Re-draw a trough plus a post-infusion level after 2–3 doses, or use Bayesian/AUC software for the next iteration.

Piperacillin-tazobactam:

  • Meta-analyses of observational data associate the combination with more AKI than vancomycin alone or vancomycin plus cefepime. The mechanism is not established, and confounding by indication is real, but the signal is consistent enough to act on when an alternative exists.
  • The decisive point is not the interaction - it is that MRSA is now confirmed and the abdominal source is being managed. De-escalate piperacillin-tazobactam to the narrowest agent the cultures and surgical course support. That removes the interaction, reduces piperacillin exposure, and is good antimicrobial stewardship regardless.
  • Do not stop vancomycin: this is MRSA bacteremia. Confirm source control, repeat blood cultures, screen for endocarditis, and involve infectious diseases.

Monitoring and co-modifiable risks:

  • Daily SCr and urine output; the combination of a rising creatinine, furosemide, and bacteremia means volume status must be reassessed - the diuretic may be contributing more than the drugs.
  • Avoid NSAIDs and iodinated contrast; minimize other nephrotoxins.
  • Aim for the lower half of the AUC window (400–500) given three concurrent renal insults.
  • Track clinical response (defervescence, repeat cultures) as the primary endpoint.

3. Suppose the isolate's MIC were reported as 2 mg/L instead of 1 mg/L. How does your interpretation and plan change?

Read the worked answer

The arithmetic changes qualitatively, not just quantitatively.

  • AUC/MIC 400–600 with an MIC of 2 requires AUC₂₄ of 800–1200 mg·h/L. That is roughly double the current exposure - approximately 2000–2500 mg q12h in this patient - which, at a CrCl in the 30s, would almost certainly produce troughs above 25–30 mg/L and a high probability of nephrotoxicity.
  • A vancomycin MIC of 2 mg/L in MRSA is a recognized marker of worse outcomes ('MIC creep'), and the probability of achieving the target without toxicity is low. Several guidelines advise against vancomycin for serious MRSA infection when the MIC is ≥2 mg/L.

Plan:

  1. Confirm and, if possible, repeat the MIC by a reference method - broth microdilution results of exactly 2 are method-dependent and can be one dilution off.
  2. Consult infectious diseases about an alternative: daptomycin 8–10 mg/kg (dose on actual body weight here; this patient is 95 kg, so 760–950 mg IV q24h) with weekly CPK and awareness that daptomycin is inactivated by pulmonary surfactant - it is fine for bacteremia but not for pneumonia.
  3. Consider combination therapy (e.g., daptomycin plus a β-lactam or ceftaroline) for persistent bacteremia, and re-emphasize source control and echocardiography.
  4. Do not chase the AUC with escalating vancomycin doses in a patient whose creatinine is already climbing.